Monday, March 17, 2025 | 12:53 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

From Cipla to Glenmark, pharma companies' double-digit growth in doubt

Govt's proposed changes in pricing policy could play spoilsport

Domestic drugmakers
Premium

Domestic drugmakers

Aneesh Phadnis Mumbai
Domestic drugmakers are targeting double-digit growth in 2018-19 on the back of product launches and expansion in new therapies but the government’s proposed pricing changes could put the brakes on their plans.

Cipla has guided for $1 billion (around Rs 67 billion) in domestic sales in 2018-19 with product launches and an uptick in its cardio-metabolic drugs. Cipla had sales of around Rs 59 billion in the last fiscal year and will have to achieve around 15 per cent growth to reach sales of $1 billion.

Glenmark too is targeting 12-15 per cent with the launch of differentiated products and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in